KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C12398)
◆英語タイトル:KYORIN Holdings Inc (4569) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12398
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年12月
◆ページ数:39
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc (4569) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kyorin Acquires Production Facility from MSD 11
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Asset Transactions 31
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Acquisition 32
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc – Key Competitors 34
KYORIN Holdings Inc – Key Employees 35
KYORIN Holdings Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Other Significant Developments 37
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 37
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kyorin Acquires Production Facility from MSD 11
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc, Key Competitors 34
KYORIN Holdings Inc, Key Employees 35
KYORIN Holdings Inc, Subsidiaries 36

List of Figures
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報(KYORIN Holdings Inc (4569) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆